M&A Deal Summary |
|
---|---|
Date | 2017-02-27 |
Target | TYSABRI |
Sector | Life Science |
Buyer(s) | Royalty Pharma |
Sellers(s) | Perrigo Company |
Deal Type | Divestiture |
Deal Value | 2.9B USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1996 |
Sector | Business Services |
Revenue | 2.4B USD (2023) |
Royalty Pharma is a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates. Royalty Pharma was formed in 1996 and is based in New York, New York.
DEAL STATS | # |
---|---|
Overall | 1 of 3 |
Sector (Life Science) | 1 of 3 |
Type (Divestiture) | 1 of 3 |
Country (United States) | 1 of 3 |
Year (2017) | 1 of 1 |
Size (of disclosed) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-04-01 |
Arteaus Therapeutics - Emgality Royalty
Cambridge, Massachusetts, United States Arteaus Therapeutics LLC - Emgality Royalty is an at-home, once monthly self-injection for the preventative treatment of episodic and chronic migraine in adults. |
Buy | $260M |
Category | Company |
---|---|
Founded | 1887 |
Sector | Life Science |
Employees | 9,140 |
Revenue | 4.7B USD (2023) |
Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo Company was founded in 1887 and is based in Dublin, Ireland.
DEAL STATS | # |
---|---|
Overall | 3 of 9 |
Sector (Life Science) | 2 of 7 |
Type (Divestiture) | 3 of 9 |
Country (United States) | 1 of 2 |
Year (2017) | 2 of 4 |
Size (of disclosed) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-01-04 |
Perrigo Company - Two ANDA Pharmaceutical Products
Ireland errigo Company PLC - Two ANDA Pharmaceutical Products includes full-ownership rights to acetaminophen injection ("acetaminophen") and testosterone undecanoate injection ("testosterone"). Acetaminophen is indicated for the management of mild to moderate pain and reduction of fever in the clinical setting. Testosterone is indicated for testosterone replacement therapy in adult males. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-08-11 |
Wavelength Pharmaceuticals
Petah Tikva, Israel Wavelength Pharmaceuticals is a developer and manufacturer of generic APIs and finished dose forms (“FDF”) with operations primarily located in Israel and supporting functions in the U.S. and India. The Business has a global customer base and a broad array of products that leverage its specialized manufacturing capabilities and core competency in complex chemistries. Wavelength Pharmaceuticals is based in Petah Tikva, Israel. |
Sell | - |